Loading...
Market
Will over 1 million doses of FluMist nasal spray vaccine be sold by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Sales reports from AstraZeneca or third-party pharmacies
Story
FDA Approves First At-Home FluMist for Self-Administration
Sep 20, 2024, 05:32 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration. This makes FluMist the first influenza vaccine that can be administered without the need for a healthcare provider. The approval, announced on Friday, covers individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. The vaccine will be available through third-party pharmacies, where individuals will complete a screening and eligibility assessment when ordering the vaccine. The approval also marks the first at-home flu vaccine in the U.S.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Less than 100,000 units • 25%
100,000 to 500,000 units • 25%
500,000 to 1 million units • 25%
More than 1 million units • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%